Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Cancer Discov. 2015 Nov 10;6(1):96–107. doi: 10.1158/2159-8290.CD-15-1056

Figure 3.

Figure 3

PF-06463922 abrogates ALK phosphorylation more effectively than crizotinib in vivo. Mice harboring NB-1643 xenografts (n = 3 per arm) were treated for 3 days with vehicle, crizotinib (100 mg/kg QD), or PF-06463922 (5 mg/kg BID, 10 mg/kg/day). Tumors were harvested 1 hour after the final drug treatment, and subjected to immunoblotting as described in Methods using antibodies against pY1278 in the activation loop of the kinase (A) or pY1604 in the C-terminal regulatory tail (B), alongside control blots for total ALK and β-actin (lower panels).